Financial Decoupling: China Biotechs Brace For Potential US Delistings, Softening Economy

US-listed Chinese biotechs face a potential double-whammy from US rules requiring accounting transparency at the risk of delisting, while other challenges loom from a general regulatory crackdown and economic softening in China, along with rising COVID-19 cases.